Trial Profile
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir in Hospitalized Adult Patients With Severe COVID-19.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 19 Jan 2021
Price :
$35
*
At a glance
- Drugs Remdesivir (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- 22 Dec 2020 Data from this and other study (NCT03652363) was used to demonstrate the use of two plots identified to be beneficial for wide use in RCTs, Results published in the Trials.
- 24 May 2020 Results published in the Trials.
- 04 May 2020 According to an Gilead Sciences media release, data from this study will be reviewed by CHMP as a part of rolling review.